Detalhe da pesquisa
1.
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
BMC Cancer
; 23(1): 191, 2023 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849918
2.
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.
Curr Gene Ther
; 24(2): 147-158, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767800
3.
The prognostic role of fasting plasma glucose levels on survival in advanced colorectal cancer patients with type II diabetes mellitus: a retrospective cohort study.
J Gastrointest Oncol
; 13(6): 3080-3089, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36636046
4.
Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer.
J Gastric Cancer
; 22(2): 107-119, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534448
5.
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection.
Front Oncol
; 11: 684627, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34109131